Company / Operating Income per Share
Royalty Pharma plc Operating Income per Share History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income per Share
$2.59
FY2025
5-year range
$2.59 / $6.99
FY2021-FY2025
Trend
-12.3%
vs FY2024
Sector context
#26 of 201
Health Care
What the data says
Royalty Pharma plc's operating income per share of $2.59 is higher than 87% of companies in the Health Care sector (FY2025). Operating Income per Share has declined for 4 consecutive years, from $6.99 in FY2021 to $2.59 in FY2025.
Based on SEC 10-K filings.
2.59 in FY2025 with a 5-year CAGR of -6.6%. Top quartile in the Health Care sector.
Declined from $3.60 to $2.59 over the past 2 years.
Health Care sector context is included.
Operating Income per Share over time
Growth rates
- 3-Year CAGR
- -15.2%
- 5-Year CAGR
- -6.6%
- 10-Year CAGR
- -
Sector benchmark
+180.0% above sector average
Key checks
Key Insights
- Royalty Pharma plc's operating income per share has declined for 4 consecutive years.
- In FY2025, operating income per share decreased 12.3% year-over-year.
- Ranks #26 out of 201 companies in the Health Care sector.
- Peak operating income per share was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score 0.91 (distress zone, below 1.8 threshold)
- Strong profit margin: 38.0%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Income per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.59 | -12.3% |
| FY2024 | $2.95 | -18.0% |
| FY2023 | $3.60 | -15.3% |
| FY2022 | $4.25 | -39.2% |
| FY2021 | $6.99 | +92.3% |
| FY2020 | $3.63 | - |
| FY2019 | - | - |
| FY2018 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026